## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 7.1% in mid entry zone (4.0-10.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (1.8%) confirms momentum alignment. Strong momentum (+2.7% 5-day acceleration). Outperforming sector by 5.5%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($25.23)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD)**
- Source: Simply Wall Street | 20251216T220957 | Somewhat-Bullish | Relevance: 100%
- ACADIA Pharmaceuticals recently received U.S. FDA approval for DAYBUE STIX, a new dye- and preservative-free powder formulation of trofinetide for Rett syndrome, offering more flexible dosing. This approval has led to a higher price target from H.C. Wainwright and supports Acadia's revenue guidance, as the company aims to solidify DAYBUE and NUPLAZID as durable revenue streams. Investors are evaluating whether this new formulation will significantly boost patient retention and long-term upside, particularly given the stock's current valuation projections.

**2. New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD)**
- Source: Simply Wall Street | 20251216T200844 | Somewhat-Bullish | Relevance: 100%
- Acadia Pharmaceuticals received FDA approval for DAYBUE STIX, a new dye- and preservative-free powder formulation of trofinetide for Rett syndrome, offering improved flexibility over the existing oral solution. While this could enhance patient retention and supports the Rett franchise, investors should note that the company's near-term earnings primarily rely on NUPLAZID. Analysts like H.C. Wainwright have raised price targets, reflecting optimism about the new formulation's long-term impact on patient retention and Acadia's revenue guidance.

**3. FDA Approves Acadia Pharmaceuticals’ Daybue Stix for Treating Rett Syndrome**
- Source: GeneOnline | 20251215T110940 | Bullish | Relevance: 100%
- The U.S. FDA has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide) for the treatment of Rett syndrome, a rare neurological disorder that primarily affects females. This approval provides a new therapeutic option for patients and caregivers, targeting the underlying symptoms of the condition. The decision follows a review of clinical trial data on the safety and efficacy of trofinetide.

**4. Acadia Pharmaceuticals stock price target raised to $37 by H.C. Wainwright**
- Source: Investing.com India | 20251216T130844 | Bullish | Relevance: 100%
- H.C. Wainwright increased its price target on Acadia Pharmaceuticals (NASDAQ:ACAD) to $37 from $32, maintaining a Buy rating after the launch of DAYBUE STIX, a new powder formulation of the company’s Rett syndrome drug. This new formulation is expected to improve patient retention and growth, leading to revised penetration assumptions and the higher price target. InvestingPro data suggests ACAD is currently undervalued and possesses strong financials with more cash than debt.

**5. FDA approves Acadia’s Daybue Stix for Rett syndrome treatment**
- Source: Pharmaceutical Technology | 20251215T220940 | Bullish | Relevance: 100%
- The US Food and Drug Administration has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a new dye and preservative-free powder formulation, for treating Rett syndrome in patients aged two years and older. This new formulation aims to offer greater flexibility in administration regarding taste and dosage volume, maintaining the same efficacy and safety profile as the existing Daybue oral solution. Daybue Stix will be available in limited quantities starting in the first quarter of 2026, with wider distribution expected early in the second quarter.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | HC Wainwright & | $37 | $32 | +16% |
| 2025-12-11 | Stifel | $25 | $24 | +4% |
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | HC Wainwright & | main | Buy |
| 2025-12-11 | Stifel | main | Hold |
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +14%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.7% over 5 days suggests accumulation.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (3 raises, avg +14%). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.6B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.73 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 33.1 |
| Current P/E | 33.1 |
| YoY Growth | -0.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 4.4% to 7.1% (+2.7% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 at 1.8% confirms short-term momentum alignment. AM_20 at 5.0% shows strong absolute momentum above own 20MA. Outperforming sector by 5.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.13% (CS: 87) | Strong |
| RSI_14 | 65.3 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.050x | Above |
| vs SMA50 | 1.145x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $26.93
- **Stop Loss:** $25.23 (6.3% risk)
- **Target:** $29.48 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 635
- **Position Value:** $17,100.55
- **Portfolio %:** 17.10%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*